SCHEMBL4973106

SCHEMBL4973106

Cc1cc([C@]2(C)CCCN2)on1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.33
CHRNB4 P30926 3/20 0.33
CHRNA3 P32297 3/20 0.33
CHRNA5 P30532 2/20 0.33
PARP1 P09874 7/20 0.32
PARP2 Q9UGN5 4/20 0.32
CDC7 O00311 2/20 0.31
CCNE1 P24864 2/20 0.31
CDK2 P24941 2/20 0.31
ROCK1 Q13464 2/20 0.31
DBF4 Q9UBU7 2/20 0.31
TNKS O95271 1/20 0.31
PARP14 Q460N5 1/20 0.31
PARP10 Q53GL7 1/20 0.31
PARP12 Q9H0J9 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
PARP4 Q9UKK3 1/20 0.31
PARP3 Q9Y6F1 1/20 0.31
CHRNA7 P36544 1/20 0.30
CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9974040 0.74 HCAR2 (0.38) CHRNB2CHRNB4CHRNA3CHRNA5CHRNA7
SCHEMBL8567997 0.69 CDC7 (0.32) PARP1PARP2CDC7CCNE1CDK2
SCHEMBL8564031 0.69 CDC7 (0.32) PARP1PARP2CDC7CCNE1CDK2
SCHEMBL15934205 0.69 KRAS (0.39) PARP1PARP2CDC7CCNE1CDK2
SCHEMBL20320352 0.67 HCAR2 (0.35) CHRNB2CHRNB4CHRNA3CHRNA5CHRNA7
SCHEMBL20320350 0.65 POLB (0.34) CHRNB2CHRNB4CHRNA3CHRNA5CHRNA7
SCHEMBL7000790 0.64 CHRNB2 (0.37) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL31382430 0.64 OPRM1 (0.38) CHRNA4HCAR2
Hydrochloric Acid SCHEMBL7000062 0.63 CHRNB2 (0.36) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL32681150 0.63 PARP1 (0.33) PARP1PARP2CDC7CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008122049-A2 METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS PARKINSON'S INSTITUTE (US) 2008-10-09 WO disclosed
EP-1126846-A1 USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER A Carlsson Research AB (SE) 2001-08-29 EP disclosed
WO-2000025783-A1 USE OF A NICOTINE RECEPTOR AGONIST IN THE TREATMENT OF OBSESSIVE COMPULSIVE DISORDER A CARLSSON RESEARCH AB (SE) 2000-05-11 WO disclosed